Despite the high sensitivity of breast magnetic resonance imaging (MRI), pathologic confirmation by biopsy is essential because of limited specificity. MRI-guided biopsy is required in patients with lesions only seen on MRI. We review preprocedural considerations and the technique of MRI-guided biopsy, challenging situations and troubleshooting, and correlation of radiologic and pathologic findings.
INTRODUCTION
The use of breast magnetic resonance imaging (MRI) is increasing for screening and diagnosis of breast cancer. MRI has greater sensitivity than other imaging modalities for the screening of women at higher risk of breast cancer, with more than half of lesions only detected on MRI (1, 2) . MRI can identify primary cancer in suspected occult breast cancer patients (3) . In addition, breast MRI most accurately depicts the extent of breast cancer (4) (5) (6) . Although the clinical relevance of additional lesions is still controversial, preoperative MRI identifies more synchronous, ipsilateral or contralateral breast cancers than mammography and ultrasound (7) (8) (9) .
However, breast MRI has limited specificity (10) . If a suspicious lesion is detected, biopsy is mandatory to avoid unnecessary surgery. In addition, biopsy under MRI guidance is required for suspected occult lesions on mammography or ultrasound.
The American College of Radiology requires performance of MRI-guided intervention or contact with available referral site when performing breast MRI (11) . The MRI guideline of the European Society of Breast Imaging also emphasizes the necessity of offering MRI-guided intervention at a site performing breast MRI (12) . The number of medical centers providing breast MRI is growing in Korea, and more MRI-guided breast biopsies are required. However, few reports describe MRI-guided breast biopsy in Korea (13, 14) . In this article, we describe preprocedural considerations and technique, and correlation of radiologic and pathologic findings in MRI-guided breast biopsy.
PREPROCEDURAL CONSIDERATIONS FOR MRI-GUIDED BREAST BIOPSY

Second-Look Studies
Second-look studies should be considered for all women with suspicious lesions on MRI. If the lesion is delineated with mammography or ultrasound, biopsy under imaging guidance using these modalities is preferred. MRI-guided biopsy is more expensive and difficult for the patient. However, the reported correlation rate of second-look ultrasound ranges from 23-57%; MRIonly lesions require an MRI-guided biopsy (15) (16) (17) (18) .
Patient Preparation
Informed consent should be obtained before the biopsy. Patients with a known contraindication for MRI or gadolinium administration should not have an MRI-guided biopsy. Patients with allergy to gadolinium or local anesthetics are also not suitable. Bleeding risk due to use of aspirin or anticoagulants or an underlying coagulation disorder is a relative contraindication for biopsy, requiring careful consideration of the risks and benefits. The patient should be able to remain prone during the biopsy for a minimum of 60 minutes. The possibility of a nonvisualized target lesion should be discussed with the patient. Even with successful visualization, the cancellation of a biopsy is sometimes necessary because of unforeseen safety issues. Complications such as hematoma, infection, and skin injury should also be discussed with the patient. For patients with breast implants, rupture is a possible complication of the biopsy. Table 1 summarizes the biopsy procedure.
MRI-GUIDED BREAST BIOPSY PROCEDURE
Positioning
The patient lies in a prone position, and a dedicated interventional breast coil is used. Either a grid or a pillar and post system is generally used. We focus on the grid system, which is most widely used (Fig. 1) . The breast within the coil is compressed by the grid. Compression pressure is adjusted for stable immobilization while preserving blood flow. The approach to a posterior mass is often difficult, requiring that sufficient breast tissue be contained in the grid to maintain distance from the chest wall. Check location of target and grid Postcontrast T1-weighted fat-saturation images (axial and sagittal)
Calculate distance from grid and fiducial marker using worksheet Skin preparation, local anesthesia, and insertion of introducer with obturator Postcontrast T1-weighted fat-saturation images (axial and sagittal)
Repeat until adequate location achieved Change obturator to VAB device and perform biopsy Post-biopsy images
Repeat biopsy if inadequate sample retrieval Marker clip insertion Post-marker-insertion image with MRI or mammography VAB = vacuum assisted biopsy Fixing a fiducial marker to the grid enhances target localization.
Equipment
MRI-guided vacuum assisted biopsy (VAB) has advantages over standard core biopsy. The larger core size results in decreased sampling error and compensates for tissue shifting during needle placement (19) . The European consensus group recommend a minimum 11-gauge probe size (20) . The MRI-guided biopsy kit consists of an introducer stylet, obturator, introducer sheath, and needle guide. The needle guide, a cube-shaped plastic block with multiple holes for the biopsy device (Fig. 2) , maintains the VAB device perpendicular to the grid. (Fig. 4) . The thickness of the needle guide should be included in the calculation. A computer-assisted diagnostic system that improves accuracy and speed of the procedure is also commercially available. About 8-13% of MRIguided biopsy target lesions are not visible at the time of biopsy (21) (22) (23) . If the target is not visible on the first postcontrast image, it is sometimes identified on a delayed image. Overpressure by the grid may interfere with breast perfusion and should be checked. A subtraction image also aids in lesion identification (Fig. 5) . If the target lesion is still not visible, short-term followup is recommended at about 6 months.
Image Acquisition and Lesion Localization
Biopsy Procedure
After standard skin preparation, local anesthesia is administered. A small nick in the skin facilitates smooth entry by the VAB device. The introducer stylet within its sheath is inserted through the needle guide to the measured depth. A twisting motion is helpful to avoid skin tenting and tissue displacement. The stylet is removed and replaced by the obturator. T1-weighted fat-saturation images are then obtained to confirm the depth and position of the introducer (24, 25) . In the case of insufficient depth, the introducer sheath can be advanced after reinsertion of the stylet; if advanced past the target lesion, the introducer is gradually withdrawn. In general, the optimal position is in the center of the target. Directional sampling can be performed with a peripheral location of the needle. When the introducer position is verified as correct, the obturator is exchanged with a VAB device. The European consensus group recommends no less than 24 samples for an 11-gauge or equivalent volume if a larger probe is used (20) . Liberman (26) reported that an 11-gauge VAB device collects 100 mg, and a 9-gauge VAB device collects 200 mg. The breast is compressed for at least 15 minutes after the biopsy.
Complications and Management
Major complications requiring surgical intervention seldom occur with MRI-guided biopsy. Complication rates are less than 5%. Bleeding and hematoma formation are most common, and can be controlled by compression. Other rare complications are skin laceration, vasovagal syncope, and infection. Termination of the procedure due to a complication is rare (19, (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) .
CHALLENGING SITUATIONS AND TROUBLESHOOTING
Targeting deep-seated lesions is prone to chest wall injury. To avoid this, traction on the breast tissue as much as possible, coil padding removal, and biopsy toward the anterior side are some (Fig. 6) . A thin breast is another challenge for MRI-guided biopsy. A generous amount of anesthetic agent helps to increase breast thickness, and a reverse compression paddle is also useful (24, 37) . VAB devices with smaller apertures or blunt tips can be used for targets in thin breasts and also those near the skin (Table 2 ).
RADIOLOGIC-PATHOLOGIC CORRELATION
As with all other image-guided biopsy techniques, MRI-guided biopsy results should be evaluated for radiologic-pathologic concordance. MRI-guided biopsy has no corresponding evaluation method such as specimen imaging in stereotactic biopsy or real-time monitoring in ultrasound-guided biopsy; therefore, radiologic-pathologic concordance requires caution. The positive predictive value of a lesion detected by MRI with subsequent MRI-guided biopsy is 16-61%; a radiologist should be aware that for radiologic-pathologic correlation, the positive predictive value is affected by the prevalence of breast cancer in a patient population (19, 30, 33, 36, (38) (39) (40) . A six-month follow-up is recommended for a benign concordant biopsy result (41) . The rate of radiology-pathology discordance is not high (0% to 10.7%); but the mean proportion of malignancies in discordant cases is 37.5%, and surgical excision is recommended for discordant lesions (Table 3 ) (19, 29, 30, 34, 36, 38, 39) .
The atypical ductal hyperplasia (ADH) upgrade rate at surgery is reportedly 25-38% (19, 30, 38, 40, 42, 43) . In ductal carcinoma in situ (DCIS), the upgrade rate ranges from 5-24% (19, 30, 38, 44) . The underestimation rates for ADH and DCIS on MRI-guided biopsy are slightly higher than those for stereotactic biopsy (21% and 11%, respectively) (45, 46) or ultrasoundguided biopsy (23.3% and 13.8%, respectively) (47). Atypical lobular hyperplasia and lobular carcinoma in situ also have a high upgrade rate (27%) (40) . Despite a limited number of studies in the underestimation rate for other high-risk lesions such as radial scars and papillomas, surgical excision for all such lesions using MRI-guided biopsy is recommended (30, 38, 40) . 
